CRISPR Therapeutics disclosed last week that it awarded CEO Sam Kulkarni 400,000 new stock options last year, bringing his total compensation package for the year, for accounting purposes ...

"Our study is a first step in dramatically expanding our repertoire of effective and safe CRISPR-Cas9 enzymes. In our manuscript, we demonstrate the utility of these PAMmla-predicted enzymes to ...

It has been 20 years since the term “genome editing” first entered the scientific lexicon, a field that was revolutionized by the development of CRISPR gene editing in 2012. But the remarkable ...

Their results are published in Nature. "Our study is a first step in dramatically expanding our repertoire of effective and safe CRISPR-Cas9 enzymes. In our manuscript we demonstrate the utility ...

Under the terms of the arrangement, EditCo will incorporate Promega’s bioluminescent and protein-labeling technologies into its CRISPR-engineered cell lines. According to the partners ...

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR ...

The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

The CRISPR specialist said that a single 50mg infusion of NTLA-2002 – which switches off a gene involved in the potentially life-threatening inflammatory attacks that characterise HAE ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $39.11, marking a +1.48% move from the previous day. Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some ...

CRISPR-based technologies have taken the world by storm thanks to the technique’s ability to edit nucleic acids. Today, researchers are not only working to understand how to better harness the ...